IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v16y2015i9p985-994.html
   My bibliography  Save this article

Some economics on personalized and predictive medicine

Author

Listed:
  • F. Antoñanzas
  • C. Juárez-Castelló
  • R. Rodríguez-Ibeas

Abstract

Although promising, the use of personalized medicine is still under scrutiny as there are important issues demanding a response. Personalized medicine may have an impact in the drug development processes, and contribute to the efficiency and effectiveness of health care delivery. Nevertheless, more accurate statistical and economic information related to tests results and treatment costs as well as additional medical information on the efficacy of the treatments are needed to adopt decisions that incorporate economic rationality. Copyright Springer-Verlag Berlin Heidelberg 2015

Suggested Citation

  • F. Antoñanzas & C. Juárez-Castelló & R. Rodríguez-Ibeas, 2015. "Some economics on personalized and predictive medicine," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(9), pages 985-994, December.
    • Handle: RePEc:spr:eujhec:v:16:y:2015:i:9:p:985-994
    DOI: 10.1007/s10198-014-0647-8
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.1007/s10198-014-0647-8
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.1007/s10198-014-0647-8?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Meckley, Lisa M. & Neumann, Peter J., 2010. "Personalized medicine: Factors influencing reimbursement," Health Policy, Elsevier, vol. 94(2), pages 91-100, February.
    2. Nils-Eric Sahlin & Göran Hermerén, 2012. "Personalised, predictive and preventive medicine: a decision-theoretic perspective," Journal of Risk Research, Taylor & Francis Journals, vol. 15(5), pages 453-457, May.
    3. Fernando Antoñanzas & R. Rodríguez-Ibeas & M. Hutter & R. Lorente & C. Juárez & M. Pinillos, 2012. "Genetic testing in the European Union: does economic evaluation matter?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(5), pages 651-661, October.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Bardey, David & Kembou, Samuel & Ventelou, Bruno, 2021. "Physicians’ incentives to adopt personalised medicine: Experimental evidence," Journal of Economic Behavior & Organization, Elsevier, vol. 191(C), pages 686-713.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Leopold, C. & Vogler, S. & Habl, C. & Mantel-Teeuwisse, A.K. & Espin, J., 2013. "Personalised medicine as a challenge for public pricing and reimbursement authorities – A survey among 27 European countries on the example of trastuzumab," Health Policy, Elsevier, vol. 113(3), pages 313-322.
    2. Rositsa Koleva-Kolarova & James Buchanan & Heleen Vellekoop & Simone Huygens & Matthijs Versteegh & Maureen Rutten-van Mölken & László Szilberhorn & Tamás Zelei & Balázs Nagy & Sarah Wordsworth & Apos, 2022. "Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options," Applied Health Economics and Health Policy, Springer, vol. 20(4), pages 501-524, July.
    3. Marta O. Soares & Simon Walker & Stephen J. Palmer & Mark J. Sculpher, 2018. "Establishing the Value of Diagnostic and Prognostic Tests in Health Technology Assessment," Medical Decision Making, , vol. 38(4), pages 495-508, May.
    4. Degtiar, Irina, 2017. "A review of international coverage and pricing strategies for personalized medicine and orphan drugs," Health Policy, Elsevier, vol. 121(12), pages 1240-1248.
    5. Veronika Kalouguina & Joël Wagner, 2020. "Challenges and Solutions for Integrating and Financing Personalized Medicine in Healthcare Systems: A Systematic Literature Review," JRFM, MDPI, vol. 13(11), pages 1-22, November.
    6. Fernando Antoñanzas & Carmelo A. Juárez-Castelló & Roberto Rodríguez-Ibeas, 2016. "Implementing personalized medicine with asymmetric information on prevalence rates," Health Economics Review, Springer, vol. 6(1), pages 1-8, December.
    7. Nævdal, Eric, 2014. "Optimal screening for genetic diseases," Economics & Human Biology, Elsevier, vol. 15(C), pages 129-139.
    8. Holloway, Kelly & Miller, Fiona A., 2022. "The Consultant's intermediary role in the regulation of molecular diagnostics in the US," Social Science & Medicine, Elsevier, vol. 304(C).
    9. Fischer, Katharina E. & Leidl, Reiner & Rogowski, Wolf H., 2011. "A structured tool to analyse coverage decisions: Development and feasibility test in the field of cancer screening and prevention," Health Policy, Elsevier, vol. 101(3), pages 290-299, August.
    10. F. Antoñanzas & C. A. Juárez-Castelló & R. Rodríguez-Ibeas, 2019. "Pre-approval incentives to promote adoption of personalized medicine: a theoretical approach," Health Economics Review, Springer, vol. 9(1), pages 1-10, December.
    11. Fernando Antoñanzas & Carmelo Juárez-Castelló & Roberto Rodríguez-Ibeas, 2015. "Is personalized medicine a panacea for health management? Some thoughts on its desirability," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(5), pages 455-457, June.
    12. Vokinger, Kerstin N. & Muehlematter, Urs Jakob, 2020. "Accessibility of cancer drugs in Switzerland: Time from approval to pricing decision between 2009 and 2018," Health Policy, Elsevier, vol. 124(3), pages 261-267.
    13. Daniel Gallacher & Nigel Stallard & Peter Kimani & Elvan Gökalp & Juergen Branke, 2022. "Development of a model to demonstrate the impact of National Institute of Health and Care Excellence cost‐effectiveness assessment on health utility for targeted medicines," Health Economics, John Wiley & Sons, Ltd., vol. 31(2), pages 417-430, February.
    14. Tracy Merlin & Claude Farah & Camille Schubert & Andrew Mitchell & Janet E. Hiller & Philip Ryan, 2013. "Assessing Personalized Medicines in Australia," Medical Decision Making, , vol. 33(3), pages 333-342, April.

    More about this item

    Keywords

    Economic model; Personalized medicine; Predictive medicine; Genetic testing; Specificity; Sensitivity; I11; I18;
    All these keywords.

    JEL classification:

    • I11 - Health, Education, and Welfare - - Health - - - Analysis of Health Care Markets
    • I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:16:y:2015:i:9:p:985-994. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.